BASH-003

BASH-003 is an investigational small molecule therapeutic being developed by Bash Biotech (also known as Bash Bio) for the treatment of Alzheimer's disease. Currently in the preclinical stage, BASH-003 is designed to target and promote the clearance of toxic protein aggregates, specifically focusing on the Microtubule-associated protein tau (MAPT), which is a hallmark of Alzheimer's pathology. The compound was identified using Bash Biotech's proprietary AI-integrated platform, which focuses on discovering orally bioavailable small molecules that trigger the clearance of neurotoxic proteins through the mitophagy pathway. By restoring cellular protein homeostasis, BASH-003 aims to halt or reverse the neurodegenerative processes associated with Tau aggregation.